Answers are grounded in this paper and cite their sources.
Background: Atherosclerosis is among the primary causes of mortality globally due to its ability to induce cardiovascular and cerebrovascular events. Osteopontin (OPN) is a pro-inflammatory cytokine that plays an important role in the development of atherosclerosis. Simvastatin, a lipid-lowering drug belonging to the statin class, is known to decrease plasma OPN levels. However, its unfavorable pharmacokinetic profile, characterized by extensive first-pass metabolism leading to poor bioavailability, has restricted its clinical use. Objectives: The present study aimed to assess the efficacy of a nano-formulation of simvastatin [folate-conjugated simvastatin silver (Ag) nano-formulation] in a cellular model of atherosclerosis. Methods: This interventional study was performed on adventitial fibroblasts obtained from rat aorta. The cell viability of aldosterone-stimulated adventitial fibroblasts was evaluated in the presence of simvastatin and its nano-formulation using the MTT (3-[4,5-dimethylthiazole-2-yl]2,5-diphenyltetrazolium bromide) assay and microscopic observation. The expression and quantification of OPN were performed using qPCR and ELISA, respectively. The presence of reactive oxygen species (ROS) was estimated using a fluorescent probe, dihydroethidine (DHE). Variation among data was computed using one-way ANOVA followed by post hoc analysis (Bonferroni post hoc test) using SPSS software (version 19.0, SPSS Inc., Chicago, IL). Results: The nano-formulation of simvastatin was most effective (P < 0.05) in retaining the viability of fibroblasts (300% at 10 μM, P < 0.001), which was significantly decreased (50% at 10 μM, P < 0.001) after aldosterone treatment. Additionally, the formulation prevented the aldosterone-induced increase in OPN expression in fibroblasts. However, ROS levels remained unaltered in all groups. Conclusions: The nano-formulation of simvastatin demonstrated a protective effect in a cellular model of atherosclerosis, likely due to its ability to prevent the increase in aldosterone-induced OPN expression. Assuming a favorable pharmacokinetic profile, owing to its reduced size and folate conjugation, the formulation warrants further investigation in the anti-atherosclerosis drug discovery program.
No takes yet. Share an insight, caveat, or question.
Khawer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: